NCI, US TOO Form Educational Partnership

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

BETHESDA, Md--It's called "Know Your Options: The National Prostate Cancer Education Program," and it's a joint effort by the National Cancer Institute and US TOO International, the world's largest men's cancer group.

BETHESDA, Md--It's called "Know Your Options: The National ProstateCancer Education Program," and it's a joint effort by the NationalCancer Institute and US TOO International, the world's largest men's cancergroup.

The two organizations have taken aim at men age 50 and older, and those40 or over who are at high risk of prostate cancer, to increase their awarenessabout the detection, diagnosis, and management of the disease.

The effort will include multicity symposia for health professionalsand lay audiences, the development of interactive software to provide informationabout prostate cancer, and enhancement of US TOO's website (http://www.ustoo.com)to help men sort through the complexities of prostate cancer management.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content